• About
  • Team
  • Portfolio
  • Case Studies
  • News
RiverVest Funds I, II & III RiverVest Fund IV Archer Seed Fund
Logo Logo Logo Logo Logo

15 May The Sugar Fix: A New Approach to Treating a Rare Glycosylation Disorder

Posted at 21:05h in Expert Insights by kelly 0 Comments

Glycosylation is crucial to the development of healthy organs and tissues. Could replacing a missing sugar help patients with a rare glycosylation disorder improve coordination and mobility? ...

Read More

12 Feb Portfolio Company Spotlight: Alleviant Medical (Chronic Heart Failure)

Posted at 18:08h in Expert Insights by kelly 0 Comments

Learn how Alleviant's no-implant approach addresses the full spectrum of chronic heart failure....

Read More

14 Nov Diabetes Treatment: A Story of Complicated Progress and Great Potential

Posted at 18:11h in Expert Insights by kelly 0 Comments

RiverVest speaks with Lyn Baranowski, CEO of portfolio company Avalyn Pharma, about who she is, what brought her to Avalyn, and what fuels her passion for building great companies....

Read More

05 Sep Meet the Leader: Lyn Baranowski, CEO of Avalyn Pharma

Posted at 10:00h in Expert Insights by kelly 0 Comments

RiverVest speaks with Lyn Baranowski, CEO of portfolio company Avalyn Pharma, about who she is, what brought her to Avalyn, and what fuels her passion for building great companies....

Read More

22 May Portfolio Company Spotlight: Engrail Therapeutics (Anxiety Disorders)

Posted at 17:10h in Expert Insights by Debbie Gerardi 0 Comments

For this Expert Insight, RiverVest spoke with Vikram Sudarsan, PhD, founder and CEO of Engrail Therapeutics about the significant unmet need for safer, more effective treatments for anxiety disorders and how the company's lead drug candidate, ENX-102, is addressing that need....

Read More

26 Feb Global Clinical Trial Investigates Novel Heart Failure Treatment

Posted at 15:15h in Expert Insights by kelly 0 Comments

RiverVest's latest Expert Insight explores the role of patient advocacy groups in therapeutic drug development for patients with rare diseases such as mitochondrial disease. ...

Read More

08 Aug Mitochondrial Challenges: Innovations in Research and Patient-Centered Care

Posted at 19:18h in Expert Insights by kelly 0 Comments

RiverVest's latest Expert Insight explores the role of patient advocacy groups in therapeutic drug development for patients with rare diseases such as mitochondrial disease. ...

Read More

13 Jun The Orphan Drug Act of 1983 by Niall O’Donnell

Posted at 18:23h in Expert Insights by kelly 0 Comments

In this article, Managing Director Niall O’Donnell, Ph.D. discusses the law that transformed orphan drug development and how one actor’s starring role in its passage spurred 40 years of prolific, life-saving innovation. ...

Read More
Thomas Melzer, Managing Director, RiverVest Venture Partners

14 Mar Managing Risks, Maximizing Investor Returns, by Tom Melzer

Posted at 15:30h in Expert Insights by Debbie Gerardi 0 Comments

In this article, Managing Director Tom Melzer breaks down RiverVest's investment strategy, which centers on managing risk and capital efficiency with one goal in mind: a successful and profitable exit that will maximize investor return. ...

Read More
logo-rivervest
St. Louis

101 S. Hanley Road, Suite 1850
St. Louis, MO 63105

Phone: (314) 726.6700

San Diego

10996 Torreyana Road, Suite 280
San Diego, CA 92121

Phone: (314) 726.6700

Cleveland

11000 Cedar Avenue
Cleveland, OH 44106

Phone: (216) 658.3982

RiverVest strives to improve the lives of patients, support entrepreneurs, and earn the trust of investors through science, strategy, and innovation.

Contact us at info@rivervest.com

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.OkLearn More